Literature DB >> 11895105

Nicotine increases the expression of high affinity nerve growth factor receptors in both in vitro and in vivo.

Ramamohana R Jonnala1, Alvin V Terry, Jerry J Buccafusco.   

Abstract

Impairment in nerve growth factor (NGF)-mediated support to basal forebrain cholinergic neurons may represent an initial insult to certain neural cells in Alzheimer's disease (AD). High affinity NGF receptor (TrkA) levels are decreased in AD brains as compared to age-matched control brains. One of the approaches suggested for the treatment of AD exploits the ability of small molecular substances to enhance the expression of endogenous growth factors and/or their receptors. The purpose of this study was to determine whether treatment with nicotine in both in vitro and in vivo settings would increase the neural expression of TrkA receptors. Using a differentiated PC12 neuronal-like system, chronic nicotine treatment increased cell surface TrkA receptor expression. Nicotine's action was blocked by co-treatment with either the non-competitive nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine or with the alpha7 nAChR-selective antagonist methyllycaconitine. Surprisingly, certain low doses of mecamylamine alone also increased TrkA receptor levels. Rats prepared with chronic indwelling intravenous catheters were continuously infused with nicotine to deliver a total dose of 12 mg/kg over 24 hr. This treatment resulted in a significant 44% increase in TrkA receptor expression in the hippocampus. As in the cell experiments, mecamylamine also increased hippocampal TrkA receptor expression. In fact, the ratio of the maximal mecamylamine response to the maximal nicotine response that was measured in vitro, i.e., 0.43 was remarkably similar to that for the in vivo experiment, i.e., 0.47. Since in our previous studies the increase in TrkA expression produced by nicotine was shown to be related to its cytoprotective actions, these results suggest that nicotine's neuroprotective actions might also be mediated through the drug's interaction with central alpha7 nAChRs and subsequent increase in TrkA receptor expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895105     DOI: 10.1016/s0024-3205(01)01529-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  13 in total

1.  Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts.

Authors:  Gouri Shanker; Jimmy L Kontos; Delrae M Eckman; Deborah Wesley-Farrington; David C Sane
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

Review 2.  Neurobiology of nAChRs and cognition: a mini review of Dr. Jerry J. Buccafusco's contributions over a 25 year career.

Authors:  Alvin V Terry; Michael W Decker
Journal:  Biochem Pharmacol       Date:  2011-06-12       Impact factor: 5.858

3.  Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.

Authors:  T Bordia; M McGregor; J M McIntosh; R M Drenan; M Quik
Journal:  Neuroscience       Date:  2015-03-24       Impact factor: 3.590

4.  Nicotine alters the proteome of two human pancreatic duct cell lines.

Authors:  Joao A Paulo
Journal:  JOP       Date:  2014-09-28

5.  Effect of amyloid peptides on the increase in TrkA receptor expression induced by nicotine in vitro and in vivo.

Authors:  Xinyu D Li; Esperanza Arias; Ramamohana R Jonnala; Shyamala Mruthinti; Jerry J Buccafusco
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

6.  MHP-133, a drug with multiple CNS targets: potential for neuroprotection and enhanced cognition.

Authors:  Jerry J Buccafusco; James C Powers; Maria A Hernandez; Mark A Prendergast; Alvin V Terry; Ramamohana R Jonnala
Journal:  Neurochem Res       Date:  2007-04-03       Impact factor: 3.996

Review 7.  Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms.

Authors:  G Mudo; N Belluardo; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2006-08-17       Impact factor: 3.575

Review 8.  Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease.

Authors:  Maryka Quik; Danhui Zhang; Matthew McGregor; Tanuja Bordia
Journal:  Biochem Pharmacol       Date:  2015-06-18       Impact factor: 5.858

Review 9.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

Review 10.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.

Authors:  Evelin L Schaeffer; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.